ClinicalTrials.gg
RecruitingNCT06286540Updated Mar 15, 2024

Evaluation of the Efficacy and Safety of Surgical Device "Lymphoblock" for Prevention of Lymphorrhea in Patients With Thoracoabdominal Aorta Repair.

An interventional study of Lymphoblock and Placebo in Aorta Abdominalis; Aneurysm and Aorta Thoracic; Aneurysm, sponsored by Petrovsky National Research Centre of Surgery. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by Petrovsky National Research Centre of Surgery · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Registered 1 year after the study started (first participant enrolled Feb 2023, registered Feb 2024).
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Randomized, double-blind, placebo-controlled study will determine the clinical efficacy and safety of Lymphoblock in the prevention of postoperative retroperitoneal chylo-/lymphorrhoea in patients with open surgical treatment of the thoracoabdominal aorta. It is planned to recruit 138 clinical observations. Efficacy will be evaluated based on clinical and laboratory data.

Read the detailed description

The study design will include patients with open surgical repair of the thoracoabdominal aorta who underwent thoracophrenolumbotomy with retroperitoneal exposure of the aorta. It is assumed the lymphoblock to reduce the incidence of postoperative lympho-/chylorrhea. Patients will be divided based on randomization into groups that will receive a lymphoblock or a placebo. It is planned to recruit 138 patients, 69 patients in each group. The drug will be used right before wound closure. The solution will be applied to the surface of the wound with further exposure and draining. Blood test and drainage discharge parameters (from the left pleural cavity and retroperitoneum) will be examined in postoperative period. The thoracic and abdominal CT and ultrasound will be performed to exclude presence of effusion and/or lymphocele.

02

Conditions studied

  • Aorta Abdominalis; Aneurysm
  • Aorta Thoracic; Aneurysm
03

In context

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

This study's planned enrollment of 138 is above the median of 66 across 228 interventional studies indexed under Aortic Aneurysm, Abdominal.

Browse Aortic Aneurysm, Abdominal studies →

Lead sponsor

Petrovsky National Research Centre of Surgery is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patient in thoracoabdominal or abdominal aorta repair underwent retroperitoneal aortic access

Exclusion criteria

Exclusion Criteria:

  • refusal to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
138 participants (estimated)

Study arms

  • Experimental
    Lymphoblock

    Patients from this group received Lymphoblock.

    Device: Lymphoblock

  • Placebo comparator
    Placebo

    Patients from this group received placebo.

    Device: Placebo

Interventions

  • DeviceLymphoblock

    1 time per surgery with the exposition for 20 minutes.

  • DevicePlacebo

    1 time per surgery with the exposition for 20 minutes.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Chylous Effusion (Сhilo-/lymphorrhea)

    This outcome will be determined by assessing the milky of the drainage discharge, and comparing the content of triglycerides, glucose, cholesterol and lactate dehydrogenase (LDH) in the drainage discharge with those in the blood plasma

    Time frame: within 10 days of starting a regular diet after surgery

  2. Number of Participants with Lymphocele

    retroperitoneal liquid formation ≥5 cm in diameter according to ultrasound after drainage removal

    Time frame: 10 days after the surgery in patient who starting a regular diet after drainage removal

Secondary outcomes

  1. The amount of drainage discharge 1

    volume of drainage discharge obtained in the first 24 hours after surgery, measured in milliliters (ml)

    Time frame: 24 hours after the surgery

  2. The amount of drainage discharge 2

    volume of drainage discharge obtained in the first 48 hours after surgery, measured in milliliters (ml)

    Time frame: 48 hours after the surgery

  3. The amount of drainage discharge 3

    volume of drainage discharge obtained in the first 72 hours after surgery, (ml)

    Time frame: 72 hours after the surgery

  4. Concentration of triglycerides in the drainage discharge

    count of triglycerides in the drainage discharge, received from drainage tube, (mg/dL)

    Time frame: 72 hours after the surgery

  5. Concentration of triglycerides in blood plasma

    count of triglycerides in the blood plasma, (mg/dL)

    Time frame: 72 hours after the surgery

  6. Concentration of cholesterol in the drainage discharge

    count of cholesterol in the drainage discharge, received from drainage tube, (mg/dL)

    Time frame: 72 hours after the surgery

  7. Concentration of cholesterol in the blood plasma

    count of cholesterol in the blood plasma, (mg/dL)

    Time frame: 72 hours after the surgery

  8. Concentration of protein in the drainage discharge

    count of total protein in the drainage discharge, received from drainage tube, (g/dL)

    Time frame: 72 hours after the surgery

  9. Concentration of protein in the blood plasma

    count of total protein in the blood plasma, (g/dL)

    Time frame: 72 hours after the surgery

  10. Concentration of albumin in the drainage discharge

    count of albumin in the drainage discharge, received from drainage tube, (g/dL)

    Time frame: 72 hours after the surgery

  11. Concentration of albumin in the blood plasma

    count of albumin in the blood plasma, (g/dL)

    Time frame: 72 hours after the surgery

  12. Concentration of lactate dehydrogenase in the drainage discharge

    count of albumin in the drainage discharge, received from drainage tube (IU/L)

    Time frame: 72 hours after the surgery

  13. Concentration of lactate dehydrogenase in the blood plasma

    count of lactate dehydrogenase in the blood plasma (IU/L)

    Time frame: 72 hours after the surgery

  14. Concentration of glucose in the drainage discharge

    Content of glucose in the drainage discharge, received from drainage tube, (mg/dL)

    Time frame: 72 hours after the surgery

  15. Concentration of glucose in the blood plasma

    Content of glucose in the blood plasma (mg/dL)

    Time frame: 72 hours after the surgery

  16. Number of Participants with Pleural effusion within 10 days

    left pleural fluid accumulations (≥500 ml) after drainage removal drainage removal

    Time frame: 10 days after the surgery in patient who starting a regular diet after drainage removal

  17. Number of Participants with Lymphocele 3 months after the surgery

    liquid formation ≥5 cm in diameter according to ultrasound after drainage removal

    Time frame: 3 months after the surgery

  18. Number of Participants with Pleural effusion 3 months after the surgery

    left pleural fluid accumulations (≥500 ml) after drainage removal

    Time frame: 3 months after the surgery

07

Study locations

1 of 1 sites recruiting
  • Petrovsky NRCS
    Moscow, 119991, Russian Federation
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2026, 36 months after the start.

Of 51 non-industry interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 61. This study's planned 36 months is below that.

Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Feb 29, 2024
StartActual
Feb 22, 2023
Primary completionEst.
Feb 2026
CompletionEst.
May 2026
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06286540
Lead sponsor
Petrovsky National Research Centre of Surgery
Responsible party
Sponsor
First posted
Feb 29, 2024
Start date
Feb 22, 2023
Primary completion
Feb 2026 (estimated)
Completion
May 2026 (estimated)
Last update
Mar 15, 2024

Study contacts

Eduard Charchyan, MD
Contact
charchmed@yahoo.com
+79262174114
Denis Breshenkov, Phd
Contact
denisbreshenkov@gmail.com
+79773439041
Eduard Charchyan, MD
principal investigator · Petrovsky NRCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion